Spots Global Cancer Trial Database for Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
Official Title: A Trial of Hypofractionation Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS Metastatic Colorectal Carcinoma (mCRC)
Study ID: NCT05292417
Conditions
Study Description
Brief Summary: To evaluate the clinical efficacy and safety of hypofractionation radiotherapy combined with sintilimab，GM-CSF and Fruquintinib in Patients With MSS Metastatic Colorectal Carcinoma (mCRC)
Detailed Description: Condition or disease:MSS Metastatic Colorectal Carcinoma (mCRC) Phase:Phase 2 Intervention/treatment: Radiation: hypofractionation radiotherapy Drug: sintilimab, GM-CSF , Fruquintinib
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Contact Details
Name: Mingquan Cai
Affiliation: The First Affiliated Hospital of Xiamen University
Role: PRINCIPAL_INVESTIGATOR
Name: Xiyi Liao
Affiliation: The First Affiliated Hospital of Xiamen University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
